Otsuka Pharmaceutical Sustainability Profile
Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical's score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka Pharmaceutical's reported carbon emissions
In 2024, Otsuka Pharmaceutical reported total carbon emissions of approximately 557,000,000 kg CO2e globally. This figure reflects a slight decrease from 2023, when the company recorded emissions of about 523,000,000 kg CO2e for Scope 1 and 2 combined. In Japan, the 2023 emissions included 109,739,000 kg CO2e from Scope 1, 1,395,000 kg CO2e from Scope 2, and significant contributions from Scope 3 emissions, totalling approximately 664,646,000 kg CO2e from purchased goods and services alone. Otsuka has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and 2 emissions by 2028, compared to 2017 levels. This target was accelerated from an original goal of 2030. The company is also working towards achieving net-zero emissions across all scopes by 2050, as part of its long-term environmental vision. The emissions data is sourced directly from Otsuka Holdings Co., Ltd., with no cascaded data from other corporate entities. Otsuka's proactive approach to climate action underscores its commitment to sustainability and reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | 2010 | 2011 | 2012 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 000,000,000 | - | - | - | - | 000,000,000 | - | - | - |
| Scope 2 | - | - | - | - | 000,000,000 | - | - | - | - | 0,000,000 | - | - | - |
| Scope 3 | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 | - | - | - | - |
How Carbon Intensive is Otsuka Pharmaceutical's Industry?
How Carbon Intensive is Otsuka Pharmaceutical's Location?
Otsuka Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Otsuka Pharmaceutical has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.